

# Conjugate Vaccine-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/C5671FD4F37EN.html>

Date: February 2018

Pages: 141

Price: US\$ 3,480.00 (Single User License)

ID: C5671FD4F37EN

## Abstracts

### Report Summary

Conjugate Vaccine-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Conjugate Vaccine industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Conjugate Vaccine 2013-2017, and development forecast 2018-2023

Main market players of Conjugate Vaccine in EMEA, with company and product introduction, position in the Conjugate Vaccine market

Market status and development trend of Conjugate Vaccine by types and applications

Cost and profit status of Conjugate Vaccine, and marketing status

Market growth drivers and challenges

The report segments the EMEA Conjugate Vaccine market as:

EMEA Conjugate Vaccine Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Conjugate Vaccine Market: Product Type Segment Analysis (Consumption

Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Pneumococcal  
Influenza  
Diphtheria Tetanus Pertussis  
Meningococcal

EMEA Conjugate Vaccine Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital  
Medical Center

EMEA Conjugate Vaccine Market: Players Segment Analysis (Company and Product introduction, Conjugate Vaccine Sales Volume, Revenue, Price and Gross Margin):

Bharat Biotech (India)  
Biological E (India)  
CSL Limited (Australia)  
GlaxoSmithKline (U.K.)  
Merck and Company (U.S.)  
Neuron Biotech (U.S.)  
Novartis AG (Switzerland)  
Pfizer (U.S.)  
Sanofi Pasteur (France)

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF CONJUGATE VACCINE**

- 1.1 Definition of Conjugate Vaccine in This Report
- 1.2 Commercial Types of Conjugate Vaccine
  - 1.2.1 Pneumococcal
  - 1.2.2 Influenza
  - 1.2.3 Diphtheria Tetanus Pertussis
  - 1.2.4 Meningococcal
- 1.3 Downstream Application of Conjugate Vaccine
  - 1.3.1 Hospital
  - 1.3.2 Medical Center
- 1.4 Development History of Conjugate Vaccine
- 1.5 Market Status and Trend of Conjugate Vaccine 2013-2023
  - 1.5.1 EMEA Conjugate Vaccine Market Status and Trend 2013-2023
  - 1.5.2 Regional Conjugate Vaccine Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Conjugate Vaccine in EMEA 2013-2017
- 2.2 Consumption Market of Conjugate Vaccine in EMEA by Regions
  - 2.2.1 Consumption Volume of Conjugate Vaccine in EMEA by Regions
  - 2.2.2 Revenue of Conjugate Vaccine in EMEA by Regions
- 2.3 Market Analysis of Conjugate Vaccine in EMEA by Regions
  - 2.3.1 Market Analysis of Conjugate Vaccine in Europe 2013-2017
  - 2.3.2 Market Analysis of Conjugate Vaccine in Middle East 2013-2017
  - 2.3.3 Market Analysis of Conjugate Vaccine in Africa 2013-2017
- 2.4 Market Development Forecast of Conjugate Vaccine in EMEA 2018-2023
  - 2.4.1 Market Development Forecast of Conjugate Vaccine in EMEA 2018-2023
  - 2.4.2 Market Development Forecast of Conjugate Vaccine by Regions 2018-2023

### **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole EMEA Market Status by Types
  - 3.1.1 Consumption Volume of Conjugate Vaccine in EMEA by Types
  - 3.1.2 Revenue of Conjugate Vaccine in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in Europe

- 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Conjugate Vaccine in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Conjugate Vaccine in EMEA by Downstream Industry
- 4.2 Demand Volume of Conjugate Vaccine by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Conjugate Vaccine by Downstream Industry in Europe
  - 4.2.2 Demand Volume of Conjugate Vaccine by Downstream Industry in Middle East
  - 4.2.3 Demand Volume of Conjugate Vaccine by Downstream Industry in Africa
- 4.3 Market Forecast of Conjugate Vaccine in EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CONJUGATE VACCINE**

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Conjugate Vaccine Downstream Industry Situation and Trend Overview

## **CHAPTER 6 CONJUGATE VACCINE MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

- 6.1 Sales Volume of Conjugate Vaccine in EMEA by Major Players
- 6.2 Revenue of Conjugate Vaccine in EMEA by Major Players
- 6.3 Basic Information of Conjugate Vaccine by Major Players
  - 6.3.1 Headquarters Location and Established Time of Conjugate Vaccine Major Players
  - 6.3.2 Employees and Revenue Level of Conjugate Vaccine Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 CONJUGATE VACCINE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Bharat Biotech (India)
  - 7.1.1 Company profile
  - 7.1.2 Representative Conjugate Vaccine Product

- 7.1.3 Conjugate Vaccine Sales, Revenue, Price and Gross Margin of Bharat Biotech (India)
- 7.2 Biological E (India)
  - 7.2.1 Company profile
  - 7.2.2 Representative Conjugate Vaccine Product
  - 7.2.3 Conjugate Vaccine Sales, Revenue, Price and Gross Margin of Biological E (India)
- 7.3 CSL Limited (Australia)
  - 7.3.1 Company profile
  - 7.3.2 Representative Conjugate Vaccine Product
  - 7.3.3 Conjugate Vaccine Sales, Revenue, Price and Gross Margin of CSL Limited (Australia)
- 7.4 GlaxoSmithKline (U.K.)
  - 7.4.1 Company profile
  - 7.4.2 Representative Conjugate Vaccine Product
  - 7.4.3 Conjugate Vaccine Sales, Revenue, Price and Gross Margin of GlaxoSmithKline (U.K.)
- 7.5 Merck and Company (U.S.)
  - 7.5.1 Company profile
  - 7.5.2 Representative Conjugate Vaccine Product
  - 7.5.3 Conjugate Vaccine Sales, Revenue, Price and Gross Margin of Merck and Company (U.S.)
- 7.6 Neuron Biotech (U.S.)
  - 7.6.1 Company profile
  - 7.6.2 Representative Conjugate Vaccine Product
  - 7.6.3 Conjugate Vaccine Sales, Revenue, Price and Gross Margin of Neuron Biotech (U.S.)
- 7.7 Novartis AG (Switzerland)
  - 7.7.1 Company profile
  - 7.7.2 Representative Conjugate Vaccine Product
  - 7.7.3 Conjugate Vaccine Sales, Revenue, Price and Gross Margin of Novartis AG (Switzerland)
- 7.8 Pfizer (U.S.)
  - 7.8.1 Company profile
  - 7.8.2 Representative Conjugate Vaccine Product
  - 7.8.3 Conjugate Vaccine Sales, Revenue, Price and Gross Margin of Pfizer (U.S.)
- 7.9 Sanofi Pasteur (France)
  - 7.9.1 Company profile
  - 7.9.2 Representative Conjugate Vaccine Product

7.9.3 Conjugate Vaccine Sales, Revenue, Price and Gross Margin of Sanofi Pasteur (France)

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CONJUGATE VACCINE**

8.1 Industry Chain of Conjugate Vaccine

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CONJUGATE VACCINE**

9.1 Cost Structure Analysis of Conjugate Vaccine

9.2 Raw Materials Cost Analysis of Conjugate Vaccine

9.3 Labor Cost Analysis of Conjugate Vaccine

9.4 Manufacturing Expenses Analysis of Conjugate Vaccine

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF CONJUGATE VACCINE**

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources  
12.3 Reference

## I would like to order

Product name: Conjugate Vaccine-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/C5671FD4F37EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5671FD4F37EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970